THOUSAND OAKS, Calif., Jan. 5, 2011 /PRNewswire/ — ImmunGene,
Inc., a privately held drug development company focused on targeted
antibody therapeutics, announced today it has entered into a
collaboration in which Cephalon Australia (a wholly owned
subsidiary of Cephalon, Inc.) will apply ImmunGene’s interferon
payload technology to up to six of its new drug targets for
cancers.
Under terms of the collaboration, Cephalon Australia will pay
undisclosed fees including an up-front payment to ImmunGene for a
four-year option to leverage ImmunGene’s novel drug development
technology in preclinical research on up to six of Cephalon
Australia’s drug candidates. Cephalon has the option to pay
ImmunGene license fees for exclusivity on each of these candidates
that it decides to move into clinical trials.
Cephalon Australia is responsible for research, clinical
development, manufacturing and commercialization of products that
result from the ImmunGene collaboration. ImmunGene is
eligible to receive considerable payments for research, clinical
and regulatory milestones for each drug candidate in the
collaboration that is commercialized, in addition to royalties on
worldwide net sales of any resulting products.
Dr. Sanjay Khare, CEO of ImmunGene, said, “This collaboration is
a validation of ImmunGene’s novel antibody function enhancement
technology that adds the power of cytokines to antibodies while
reducing the systemic toxicity of the cytokines.” Dr. Raj
Sachdev, ImmunGene’s Chief Operating Officer, added, “We are
pleased to have Cephalon Australia as a partner with its strong
commitment to advancing this new class of protein
therapeutics.”
ImmunGene is leveraging promising science to tap the power of
the immune system to develop therapeutic antibodies with increased
efficacy and superior safety compared to existing therapies.
ImmunGene’s breakthrough technology platform, available for
non-exclusive licensing, offers phar
‘/>”/>
